En definitiva que PM01183 Beneficiaría a las Pacientes con Cáncer de Mama Resistente y Tambien Beneficiaria a los Farmacos y Tratamientos de Terapia Standar que se usan hoy en Día .Dr Cristina Cruz - Vall d'Hebron Instituto de Oncología, Barcelona, Spain
Dr Cruz speaks with ecancer at ESMO 2016 about trials for lurbinectidin in patients for whom PARP inhibition is no longer and option.
She describes the mechanisms by which resistance to other medications can be subverted by lurbinectidin, and reports its suitability even for tumours with resistance to standard therapy cisplatin.
Lurbinectidin is discussed further by Dr Judith Balmaña, who spoke with ecancer here.